1. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Issue 10367 (3rd December 2022) Authors: Schlaich, Markus P; Bellet, Marc; Weber, Michael A; Danaietash, Parisa; Bakris, George L; Flack, John M; Dreier, Roland F; Sassi-Sayadi, Mouna; Haskell, Lloyd P; Narkiewicz, Krzysztof; Wang, Ji-Guang; Reid, Christopher; Schlaich, Markus; Katz, Ivor; Ajani, Andrew; Biswas, Sinjini; Esler, Murray; ... Journal: Lancet Issue: Volume 400:Issue 10367(2022) Page Start: 1927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fluid retention and heart failure in the PRECISION trial – Authors' reply. Issue 10385 (22nd April 2023) Authors: Schlaich, Markus P; Bellet, Marc; Weber, Michael A; Bakris, George L; Wang, Ji-Guang Journal: Lancet Issue: Volume 401:Issue 10385(2023) Page Start: 1335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan. Issue 7 (9th June 2022) Authors: Danaietash, Parisa; Verweij, Pierre; Wang, Ji‐Guang; Dresser, George; Kantola, Ilkka; Lawrence, Mary Katherine; Narkiewicz, Krzysztof; Schlaich, Markus; Bellet, Marc Journal: Journal of clinical hypertension Issue: Volume 24:Issue 7(2022) Page Start: 804 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Issue 4 (April 2020) Authors: Verweij, Pierre; Danaietash, Parisa; Flamion, Bruno; Ménard, Joël; Bellet, Marc Journal: Hypertension Issue: Volume 75:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗